Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-01-09 Sale |
2024-01-11 7:59 pm |
AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer |
7,417 | $20.14 | $149,367 | 78,614 (Direct) |
View |
| 2024-01-02 Sale |
2024-01-04 6:06 pm |
AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer |
2,583 | $20.12 | $51,967 | 54,199 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2024-03-15 Option Award(A) |
2024-03-29 4:17 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer |
30,000 | $0 | 31,914 (Direct) |
View |
| 2024-03-15 Option Award |
2024-03-18 7:28 pm |
N/A 2034-03-14 |
AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer |
90,000 | $0 | 91,914 (Direct) |
View |
| 2024-01-09 Exercise |
2024-01-11 7:59 pm |
N/A 2030-01-22 |
AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer |
7,417 | $0 | 78,614 (Direct) |
View |
| 2024-01-09 Exercise |
2024-01-11 7:59 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer |
5,000 | $6.6 | 78,614 (Direct) |
View |
| 2024-01-09 Exercise |
2024-01-11 7:59 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer |
2,417 | $0.42 | 78,614 (Direct) |
View |
| 2024-01-02 Exercise |
2024-01-04 6:06 pm |
N/A 2030-01-22 |
AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer |
2,583 | $0 | 54,199 (Direct) |
View |
| 2024-01-02 Exercise |
2024-01-04 6:06 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer |
2,583 | $0.42 | 54,199 (Direct) |
View |
| 2023-02-15 Option Award |
2023-02-17 7:19 pm |
N/A 2033-02-14 |
AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer |
62,200 | $0 | 62,200 (Direct) |
View |
| 2022-05-12 Option Award |
2022-05-16 9:16 pm |
N/A 2032-05-11 |
AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer |
66,000 | $0 | 66,000 (Direct) |
View |
Ownership |
2022-03-24 9:27 pm |
N/A 2030-01-22 |
AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer |
0 | $0 | 141,174 (Direct) |
View |